Nurosene Health Inc. announced that Dr. Luca Pani has been appointed Chief Innovation and Regulatory Officer. Dr. Pani is an Academic both at the University of Miami in the US and in Modena, Italy and the former Director-General of the Italian Medicines Agency, where he managed a multi-billion-dollar budget for drug expenditures and negotiations on behalf of the Italian National Health System. He has served as a member of the Board of Directors for the Committee for Human Medicines and the Scientific Advice Working Party for the European Medicines Agency (EMA) in London (2010-2017) and was elected as Chair of the EU Telematics Committee overlooking the EMA databases transition plan.

Further, Dr. Pani is the coordinator of FACILITATE, the last IMI-2 project funded by the European Commission (January 2022- December 2025) and the Chief of Clinical Operations and Strategic Development of Relmada Therapeutics, USA. Dr. Pani is the author of over 200 peer-reviewed scientific publications, and a recognized expert in basic and clinical pharmacology and regulatory science with particular emphasis on health technology assessments linked with large web-based clinical datasets to guide novel negotiation strategies for the reimbursement of precision medicines. Luca was the VP for Regulatory Strategy and Market Access Innovation at VeraSci where, among other matters, provided scientific strategic planning on the FDA Qualification Program for the Pathway eClinical platform.

This supported the company for a highly successful USD 330 million exit to WCG Clinical, where Dr. Pani continues to serve in the same role. Dr. Luca Pani was previously an Advisor before joining the Company in this more integral capacity.